Osteopenia Treatment Market: Overview
Thinning of bone mass is known as Osteopenia. Osteopenia is considered to be a serious risk factor for osteoporosis. Osteopenia is commonly observed in people aged above 50 who do not have osteoporosis but have average bone density. Smoking and drinking can affect the calcium level in the body, leading to weakening of bones. High salt, caffeine and soda consumption can also lead to osteopenia. Osteopenia treatment is a must for people above the age of 50. Healthy lifestyle plays a very important role in strengthening of bones. Regular exercise and healthy diet improve bone density. Developing healthy habits and osteopenia treatment methods can slow osteopenia and strengthen bones and prevent osteoporosis. Osteopenia treatment includes medications, which include bisphosphonate medications, such as ibandronate (Boniva), alendronate (Fosamax), risedronate (Actonel), zoledronate (Reclast) and raloxifene (Evista). Calcium and vitamin D supplements are also a part of osteopenia treatment. According to the National Osteoporosis Foundation, women aged 65 years and above & men aged 70 years and above should be tested for osteopenia. Also, adults aged 50 and above with a fractured bone, postmenopausal women, adults taking medication, such as prednisone or other steroids, and prone to medical conditions associated with bone loss, such as rheumatoid arthritis, should be tested for osteopenia. These group of people are at a high risk of developing osteopenia and osteoporosis. All these factors will act as driving factors for the growth of the osteopenia treatment market.
Get Free Exclusive Sample Copy of This Report @ https://www.factmr.com/connectus/sample?flag=S&rep_id=2579
Osteopenia Treatment Market: Drivers and Restraints
The growing aging population is one of the key factors responsible for the growth of osteopenia treatment market. Aging population is always at a high risk of osteopenia as aging causes loss of bone density. Moreover, increasing alcohol consumption is another factor that will drive the growth of the osteopenia treatment market. However, lack of awareness about osteopenia treatment may restraint the growth of the market. Additionally, the high cost of treatment and unavailability of treatments options in developing countries will also hamper the growth of the osteopenia treatment market.
Osteopenia Treatment Market: Overview
The global market for osteopenia treatment is expected to witness high growth during the forecast period. Increasing the patient pool and unhealthy diet and lifestyle choices are responsible for boosting the osteopenia treatment market. However, the growth of the osteopenia treatment market will be limited by several side-effects caused by calcium and vitamin D supplements, such as muscle weakness, bone pain, lack of energy, etc. Additionally, lack of knowledge regarding osteopenia treatment is another factor further expected to hamper the growth of osteopenia treatment market during the forecast period.
Osteopenia Treatment Market: Regional Outlook
Geographically, the global osteopenia treatment market is segmented into North America, Latin America, Europe, Asia-Pacific excluding Japan (APEJ), Japan and the Middle East & Africa (MEA). North America, followed by Europe, is expected to be the leading market in the global osteopenia treatment market owing to the advanced healthcare spending and infrastructure and increasing treatment coverage by Medicare and Medicaid in the US. The Osteopenia treatment market in Asia Pacific excluding Japan is expected to show significant CAGR growth due to increasing patient pool due to the growing aging population.
Ask For Customized Report @ https://www.factmr.com/connectus/sample?flag=RC&rep_id=2579
Osteopenia Treatment Market: Key Players
The global osteopenia treatment market is highly fragmented. Examples of some of the key players operating in the global osteopenia treatment market are Bayer, Primus Pharmaceuticals, Inc., Eurotec Medical Systems s.r.l., GE Healthcare, Hologic Inc., Osteosys Corp., Swissray, DMS Imaging, Medonica Co. Ltd., Demetech AB and others.
For more information on this report, please visit:https://www.factmr.com/report/2579/osteopenia-treatment-market